More CEO watchers put Gilead's Martin on their 'best of 2014' lists

End-of-year bouquets are piling up for Gilead Sciences ($GILD) CEO John Martin. After winning top reviews from the Harvard Business Review for his 2014 performance, Martin has picked up a "best CEO" nod from a prof at Dartmouth's Tuck School of Business. And the investing site Motley Fool puts him among the year's three "most exceptional" corporate chiefs. Report

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.